SCHEMBL4770853

SCHEMBL4770853

CS(=O)(=O)N(CC1CCCN1Cc1ccc(F)cc1)c1ccc(C(=O)NCc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 2/20 0.43
RORC P51449 3/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DGAT2 Q96PD7 1/20 0.41
GAA P10253 2/20 0.41
NAMPT P43490 1/20 0.40
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC1 Q13547 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MCHR1 Q99705 1/20 0.38
CCR2 P41597 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770850 0.81 NAMPT (0.44) RORCLMNADGAT2NAMPTALDH1A1
SCHEMBL4769756 0.79 LMNA (0.47) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4777592 0.78 LMNA (0.44) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4776523 0.77 LMNA (0.45) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4794402 0.77 LMNA (0.45) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4767917 0.77 LMNA (0.45) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4767910 0.77 LMNA (0.45) RORCLMNASMN1; SMN2GAANAMPT
SCHEMBL4777340 0.75 GAA (0.52) RORCLMNASMN1; SMN2GAA
SCHEMBL4777712 0.75 GAA (0.54) LMNASMN1; SMN2GAAALDH1A1POLB
SCHEMBL5567955 0.73 GAA (0.52) RORCLMNASMN1; SMN2DGAT2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 DDR1 2424/4885RORC 1743/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.